Morepen Laboratories Ltd.
•Add ratio to table
ABOUT
AI Sector View
AI GENERATEDHealthcare
This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.
PROS
- Company has delivered good profit growth of 25.7% CAGR over last 5 years
- Company is almost debt free
- Latest quarter profit grew 570.0% YoY, showing strong momentum
- Company comfortably covers its interest (20.4x coverage)
CONS
- Poor cash conversion - profits are not backed by operating cash flow (CFO/PAT 0.02x)
- Promoter holding has decreased over last 2 years: -2.6pp
- Company has a low return on equity of 10.0% over last 3 years
- Total debt has risen sharply - up 180.1% year on year
- Free cash flow has been persistently negative
- Equity base is being diluted - shares outstanding up 14.7%
* The pros and cons are machine generated based on quantitative rules.
Peer comparison
| Name | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | 1904.00 | 37.77 | 456833.38 | 0.84 | 2901.23 | 26.53 | 15299.88 | 10.98 | 19.11 | 28.81 |
| DIVISLAB | 9245.00 | 83.91 | 245425.70 | 0.32 | 902.00 | 65.50 | 3080.00 | 27.80 | 21.51 | 40.75 |
| TORNTPHARM | 4924.70 | 85.89 | 187319.76 | 0.77 | 566.00 | 3.28 | 4921.00 | 57.32 | 19.27 | 33.81 |
| ZYDUSLIFE | 1135.00 | 25.09 | 113216.68 | 0.09 | 990.20 | -34.90 | 8017.00 | 23.97 | 21.39 | 24.54 |
| CIPLA | 1389.00 | 33.29 | 112211.54 | 0.94 | 785.55 | -39.18 | 7119.28 | 4.13 | 16.00 | 16.73 |
| LAURUSLABS | 1872.15 | 92.52 | 101154.55 | 0.11 | 3620.70 | 2139.42 | 20263.10 | 1191.00 | 18.20 | 31.50 |
| LUPIN | 2135.00 | 17.66 | 97626.26 | 0.84 | 1416.98 | 16.01 | 8276.89 | 34.28 | 28.86 | 29.59 |
| MANKIND | 2345.00 | 47.42 | 96859.07 | 0.04 | 574.09 | 29.12 | 4030.59 | 12.89 | 13.24 | 26.30 |
| DRREDDY | 1155.00 | 29.92 | 96405.53 | 0.69 | 435.60 | -69.10 | 8099.80 | -5.21 | 13.75 | 10.63 |
| AUROPHARMA | 1627.00 | 25.22 | 93613.98 | 0.25 | 1032.03 | 25.22 | 9150.35 | 17.44 | 12.76 | 20.54 |
| GLENMARK | 2458.80 | 38.60 | 69393.40 | 0.10 | 482.83 | 927.88 | 4018.48 | 31.35 | 20.35 | 20.03 |
| MOREPENLAB | 117.40 | 45.78 | 6432.98 | 0.17 | 56.35 | 393.96 | 570.13 | 34.07 | 15.48 | 14.48 |
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 369 | 381 | 395 | 393 | 386 | 384 | 403 | 382 | 391 | 370 | 458 | 463 | 541 | |
| 344 | 352 | 344 | 336 | 337 | 341 | 372 | 352 | 372 | 342 | 416 | 440 | 474 | |
| Operating Profit | 25 | 30 | 51 | 56 | 49 | 43 | 32 | 30 | 19 | 28 | 42 | 23 | 67 |
| OPM % | 6.72% | 7.81% | 12.95% | 14.30% | 12.61% | 11.22% | 7.83% | 7.90% | 4.84% | 7.56% | 9.15% | 5.04% | 12.35% |
| 2 | 3 | 4 | 4 | 3 | 5 | 5 | 3 | 4 | 6 | 4 | 9 | 5 | |
| Interest | 0 | 0 | 2 | 1 | 1 | 1 | 1 | 4 | 4 | 4 | 4 | 4 | 5 |
| Depreciation | 5 | 5 | 6 | 7 | 4 | 4 | 5 | 12 | 8 | 11 | 10 | 1 | 8 |
| Profit before Tax | 22 | 27 | 47 | 53 | 47 | 43 | 30 | 17 | 11 | 19 | 31 | 28 | 72 |
| Tax % | 26.99% | 27.11% | 25.46% | 24.19% | 25.50% | 25.50% | 25.31% | 31.16% | 28.99% | 23.81% | 25.24% | 27.14% | 25.16% |
| Net Profit | 16 | 20 | 35 | 40 | 35 | 32 | 23 | 12 | 8 | 14 | 24 | 20 | 54 |
| 0.31 | 0.39 | 0.69 | 0.78 | 0.69 | 0.60 | 0.41 | 0.20 | 0.15 | 0.26 | 0.43 | 0.37 | 0.99 |
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 452 | 548 | 561 | 717 | 792 | 1,112 | 1,449 | 1,339 | 1,538 | 1,555 | 1,831 | |
| 388 | 487 | 501 | 652 | 728 | 1,000 | 1,320 | 1,262 | 1,376 | 1,401 | 1,671 | |
| Operating Profit | 64 | 60 | 60 | 65 | 64 | 112 | 129 | 77 | 162 | 153 | 160 |
| OPM % | 14.19% | 11.05% | 10.75% | 9.07% | 8.14% | 10.10% | 8.91% | 5.77% | 10.52% | 9.87% | 8.74% |
| -3 | 4 | 4 | 4 | 9 | 12 | 20 | 6 | 13 | 16 | 24 | |
| Interest | 10 | 7 | 4 | 2 | 2 | 2 | 2 | 2 | 4 | 7 | 17 |
| Depreciation | 35 | 34 | 33 | 38 | 34 | 28 | 21 | 18 | 22 | 24 | 29 |
| Profit before Tax | 16 | 23 | 26 | 29 | 37 | 94 | 126 | 63 | 149 | 138 | 150 |
| Tax % | -0.88% | 0.00% | 0.00% | 0.00% | 13.74% | 0.00% | 19.50% | 26.65% | 25.53% | 26.17% | 25.37% |
| Net Profit | 16 | 23 | 26 | 29 | 32 | 94 | 101 | 46 | 111 | 102 | 112 |
| EPS | 0.35 | 0.52 | 0.58 | 0.64 | 0.72 | 2.09 | 1.94 | 0.92 | 2.17 | 1.85 | — |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 10.79% | — |
COMPOUNDED SALES GROWTH
- 10 Years:
- 15%
- 5 Years:
- 14%
- 3 Years:
- 2%
COMPOUNDED PROFIT GROWTH
- 10 Years:
- 68%
- 5 Years:
- 26%
- 3 Years:
- 0%
STOCK PRICE CAGR
- 10 Years:
- 17%
- 5 Years:
- 16%
- 3 Years:
- 42%
- 1 Year:
- 130%
RETURN ON EQUITY
- 10 Years:
- 13%
- 5 Years:
- 15%
- 3 Years:
- 10%
- Last Year:
- 10%
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| 90 | 90 | 90 | 90 | 90 | 90 | 96 | 102 | 102 | 110 | |
| 119 | 134 | 161 | 187 | 217 | 311 | 476 | 678 | 787 | 1,072 | |
| 68 | 170 | 16 | 13 | 15 | 19 | 21 | 27 | 27 | 81 | |
| Trade Payables | 107 | 116 | 165 | 157 | 158 | 192 | 217 | 213 | 267 | 338 |
| 150 | 38 | 159 | 172 | 181 | 235 | 223 | 85 | 96 | 120 | |
| Total Liabilities | 535 | 548 | 591 | 619 | 662 | 847 | 1,033 | 1,106 | 1,279 | 1,721 |
| 216 | 191 | 182 | 153 | 135 | 144 | 156 | 171 | 217 | 366 | |
| Capital Work in Progress | 0 | 0 | 0 | 0 | 0 | 2 | 14 | 17 | 24 | 28 |
| 118 | 118 | 118 | 118 | 119 | 119 | 118 | 118 | 126 | 205 | |
| 41 | 62 | 74 | 91 | 132 | 170 | 258 | 211 | 220 | 286 | |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 317 | 294 | |
| Cash & Bank | 4 | 7 | 6 | 32 | 38 | 67 | 46 | 56 | 50 | 46 |
| 156 | 170 | 211 | 226 | 238 | 346 | 441 | 533 | 325 | 496 | |
| Total Assets | 535 | 548 | 591 | 619 | 662 | 847 | 1,033 | 1,106 | 1,279 | 1,721 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| 54 | 49 | 61 | 15 | 16 | 49 | -44 | -86 | 77 | 29 | |
| Cash from Investing | -27 | -15 | -24 | -10 | -12 | -69 | -23 | -36 | -84 | -280 |
| Cash from Financing | -28 | -31 | -38 | -0 | 5 | 47 | 66 | 144 | 0 | 260 |
| -5 | 3 | -1 | 4 | 3 | 28 | -25 | 6 | -6 | 9 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| PER SHARE | ||||||||||
| EPS (₹) | 0.35 | 0.52 | 0.58 | 0.64 | 0.72 | 2.10 | 2.12 | 0.90 | 2.17 | 1.85 |
| Book Value (₹) | 4.65 | 4.99 | 5.57 | 6.17 | 6.83 | 8.92 | 11.97 | 15.26 | 17.39 | 21.56 |
| Dividend per Share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.20 |
| Cash EPS (₹) | 1.13 | 1.26 | 1.32 | 1.48 | 1.48 | 2.72 | 2.56 | 1.26 | 2.60 | 2.30 |
| PROFITABILITY | ||||||||||
| Operating Margin % | 14.17% | 11.73% | 11.38% | 9.58% | 9.33% | 11.16% | 10.29% | 6.20% | 10.52% | 9.87% |
| Net Margin % | 3.42% | 4.23% | 4.66% | 3.99% | 4.08% | 8.47% | 6.97% | 3.45% | 7.21% | 6.53% |
| ROE % | 7.84% | 10.69% | 11.00% | 10.84% | 11.06% | 26.61% | 20.77% | 6.84% | 13.29% | 9.81% |
| ROCE % | 6.60% | 7.78% | 7.83% | 7.74% | 10.82% | 24.54% | 23.73% | 9.15% | 17.71% | 13.29% |
| 3.05% | 4.28% | 4.59% | 4.73% | 5.05% | 12.49% | 10.75% | 4.32% | 9.30% | 6.77% | |
| EFFICIENCY | ||||||||||
| Debtor Days | 51 | 54 | 63 | 59 | 56 | 45 | 48 | 65 | 68 | 72 |
| Inventory Days | 30 | 34 | 44 | 42 | 51 | 50 | 54 | 64 | 51 | 59 |
| Payable Days | 124 | 124 | 153 | 131 | 118 | 93 | 81 | 93 | 97 | 119 |
| -43 | -35 | -46 | -30 | -10 | 2 | 20 | 36 | 22 | 12 | |
| FINANCIAL HEALTH | ||||||||||
| Debt to Equity (x) | 0.20x | 0.75x | 0.53x | 0.47x | 0.04x | 0.04x | 0.03x | 0.03x | 0.03x | 0.07x |
| Interest Coverage (x) | 2.50x | 4.10x | 7.08x | 14.82x | 20.05x | 53.71x | 52.75x | 32.83x | 43.45x | 20.37x |
| 0.97x | 0.58x | 0.70x | 0.88x | 1.06x | 1.31x | 1.68x | 2.51x | 2.39x | 2.40x | |
| GROWTH | ||||||||||
| Revenue Growth % | 22.20% | 21.01% | 2.43% | 27.89% | 10.42% | 40.46% | 30.28% | -7.62% | 14.84% | 1.10% |
| Operating Profit Growth % | 36.35% | -1.79% | -0.61% | 7.65% | 7.56% | 68.03% | 20.15% | -44.34% | 110.03% | -3.01% |
| Net Profit Growth % | 2609.60% | 46.83% | 12.72% | 9.57% | 13.00% | 191.49% | 7.23% | -54.24% | 139.90% | -8.44% |
| 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 139.90% | -14.59% | |
| VALUATION | ||||||||||
| P/E (x) | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 19.38x | 25.81x |
| P/B (x) | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 2.42x | 2.22x |
| Dividend Yield % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.42% |
| 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 12.20x | 15.69x |
Documents
Corporate disclosures, annual reports, credit ratings, and concall transcripts
2026-09-03 - Newspaper publication for completion of dispatch of the notice of 41st AGM and Annual report for the FY 2025-26
2026-09-02 - Morepen Laboratories Limited has informed the Exchange regarding 'Morepen Laboratories Limited has informed the Exchange regarding 'Letter To Members, (No E-Mail Id Registered), Comprising Weblink Of The Annual Report : 2025-26'.'.
2026-09-02 - Morepen Laboratories Limited has informed the Exchange about Shareholders meeting
2026-08-26 - Newspaper publication-information relating to 41st Annual General Meeting, Dividend and Record Date
2026-08-06 - Morepen Laboratories Limited has informed the Exchange about allotment of equity shares by Morepen RX Limited, wholly owned subsidiary, to the company
2026-08-05 - Morepen Laboratories Limited has informed the Exchange about Newspaper Publication - Financial Results for the quarter ended June 30, 2026
2026-08-04 - Monitoring agency report for the quarter ended June 30, 2026
2026-08-04 - Morepen Laboratories Limited has informed the Exchange about Intimation of 41st Annual General Meeting scheduled to be held on September 26, 2026
2026-08-04 - Morepen Laboratories Limited has informed the Exchange regarding re- appointment of Mr. Sushil Suri as Chairman & Managing Director of the company w.e.f. October 20, 2026.
News
Recent coverage and analyst commentary for MOREPENLAB
Loading news…
AI Stock Analyst
Morepen Laboratories Ltd.
Sign in to Chat with AI
Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.
✨ Sign In to ChatFree 5nance Account

